X4 Pharmaceuticals, Inc Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
X4 Pharmaceuticals, Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2019 to Q3 2024.
  • X4 Pharmaceuticals, Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $0.000.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $0 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $0 Jun 30, 2024 10-Q 2024-08-08
Q4 2023 $0 Dec 31, 2023 10-Q 2024-11-13
Q1 2020 $3M Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $0 Dec 31, 2019 10-Q 2020-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.